ArticleBMC cancer2026
Supportive care challenges in a resource limited oncology setting: prevalence and management of anthracycline and vinca alkaloid extravasation in Sudan.
Article in BMC cancer, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundChemotherapy extravasation is a serious complication of cancer treatment, particularly with vesicant agents such as anthracyclines and vinca alkaloids. Data from low-resource settings, particularly in Sudan remain limited. Therefore, this study aimed to determine the prevalence, clinical characteristics, associated factors, and management practices of anthracycline and vinca alkaloid extravasation.
methodsA prospective cohort study was conducted from March to April 2023 including cancer patients receiving anthracyclines and/or vinca alkaloids at Khartoum Oncology Hospital, Sudan. Clinical and demographic data were collected using a structured form. Extravasation was assessed and graded using CTCAE v4.0. Data were analyzed using descriptive statistics and chi-square testing.
resultsAmong 264 patients, 193 (73.1%) were female and 92 (34.8%) were aged 46–60 years. Breast cancer was the most common diagnosis 145 (54.9%). The prevalence of extravasation was 22 (8.3%); all cases occurred in patients who received chemotherapy via peripheral intravenous access. Most events occurred during previous cycles 14 (63.6%) and at first dose administration 11 (50.0%). The most frequent symptoms were phlebitis 17 (77.3%) and pain 13 (59.1%), with severe tissue injury in 5 patients (22.7%). Grade 2 extravasation was most common 17 (77.3%). No patients received pharmacological antidotes or supportive measures beyond stopping chemotherapy in 3 cases (14%). No significant associations were observed between extravasation and demographic or clinical variables (p > 0.05).
conclusionThis study revealed a high prevalence of extravasation among patients receiving anthracyclines and vinca alkaloids, along with major deficiencies in management practices. The implementation of standardized protocols, staff training, and access to antidotes is urgently needed to improve patient safety in resource-limited oncology settings.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.